Aug 31, 2023 7:00am EDT Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
Aug 24, 2023 7:10am EDT Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome
Aug 18, 2023 7:00am EDT Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
Jul 17, 2023 7:00am EDT Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
Jun 29, 2023 7:00am EDT Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
Jun 13, 2023 7:00am EDT Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
Jun 02, 2023 7:00am EDT Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
Jun 01, 2023 7:00am EDT Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
May 30, 2023 7:00am EDT Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
